Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs
LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer.
In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined.
As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources.
'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.'
'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.'
About APAPP
APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Contacts:
APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@pulmapp.com (719) 425-7040
Biodesix:Natalie St. Denis, Director Corporate Communicationsnatalie.stdenis@biodesix.com (720) 925-9285
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
an hour ago
- Axios
Where the 988 mental health hotline is used most — and least
Use of the 988 national suicide prevention and mental health hotline remains uneven across states, a new analysis finds. Why it matters: The service was launched nearly three years ago to help address America's mental health crisis — but gaps persist. Driving the news: Alaska (45.3 contacts per 1,000 people), Vermont (40.2) and New York (38.8) had the highest 988 contact rates among states in 2024, per new research published in JAMA Network Open. Delaware (12.5), Alabama (14.4) and Florida (15.6) had the lowest. The big picture: The 988 service fielded more than 16.3 million calls, texts and chats between July 2022 and the end of 2024. The national contact rate was 48.9 per 1,000 people during that period, and 23.7 in 2024 alone. How it works: "Contacts" include all calls, texts and chats sent to 988, including those forwarded along to more specific services, like the Veterans Crisis Line and the LGBTQ+ Line. Geography for calls and chats was assigned based on users' phone numbers, while texts were assigned by ZIP codes shared during pre-chat surveys. What they're saying: Several factors may be contributing to the state and regional differences in 988 use, says study author Jonathan Purtle, associate professor and director of policy research at New York University's School of Global Public Health. That includes differences in how 988 is being advertised by states and cities, as well as political attitudes. Many Americans remained unfamiliar with 988 as of last summer, per Ipsos polling. And surveys have found that Democrats are more likely than Republicans to use 988, Purtle says: "We see this shake out in the map — in the South and more right-leaning places, we see lower volume." Caveat: Less populous states have more variability due to their relatively smaller sample sizes, Purtle notes. The latest: The Trump administration's proposed Health and Human Services budget would cut 988 services specifically tailored for LGBTQ+ youth, Axios' Avery Lotz reports. What's next: Last year's nationwide 988 contact rate was less than half the rate of adult emergency room visits related to mental health, the analysis finds, despite ERs' cost and access issues.
Hamilton Spectator
an hour ago
- Hamilton Spectator
Fentanyl czar says government's border bill will help in fight against lethal drug
OTTAWA - Canada's fentanyl czar says the fight against the deadly opioid would get a boost from proposed new tools for law enforcement in the Liberal government's recently tabled border bill. Kevin Brosseau, the federal point person on fentanyl, welcomes provisions in the Strong Borders Act to increase inspection powers, give police easier access to information, crack down on money laundering and improve control of chemicals used to make the drug. Brosseau was appointed fentanyl commissioner in February in response to the White House's vocal concerns about the southbound flow of the synthetic opioid into the United States — criticism it used to justify tariffs against Canada. In an interview, Brosseau said Canada is 'not the significant source' of fentanyl entering the United States, but reiterated his stance that being the source of any of the drug is a concern because small amounts can have devastating effects. Brosseau, a former senior Mountie, said his American counterparts have expressed 'deep appreciation' for Canada's efforts to address fentanyl, given the U.S. focus on hardening the border and protecting the homeland. He said they want to take additional steps in 'a collaborative approach' with Canada to address any gaps in areas such as information sharing. As a result, Brosseau said, his message of integrating and amplifying the work on fentanyl north of the border 'has been well received' by the Americans. 'We know domestically, in communities across this country, there is a problem with fentanyl production, supply, trafficking and use,' he said. An average of about 21 people a day are dying in Canada from using the drug, 'and that's what incentivizes me to act and do something.' The Liberal government's wide-ranging border bill has drawn pointed criticism from civil libertarians and refugee protection advocates. The legislation contains several elements Brosseau sees as helpful in tackling fentanyl, including a requirement that owners and operators at certain ports provide facilities for the Canada Border Services Agency to examine and detain goods bound for export. The bill would also remove barriers that prevent police from searching mail to advance a criminal investigation, where authorized to do so under the law, and expand Canada Post's inspection authority to open mail. The legislation would also make it easier for authorities to access information about internet subscribers, enable the health minister to more rapidly control precursor chemicals that can be used to produce illicit drugs and introduce new restrictions on large cash transactions. Brosseau suggested a comprehensive approach is key because, otherwise, fighting fentanyl producers and traffickers becomes a game of whack-a-mole, with a new vulnerability popping up as soon as one is eliminated. 'Criminal organizations are incredibly adept at figuring out what the weak points are, and when the weak points are found, they will be exploited until you close it off,' he said. The proposed legislation builds on earlier Canadian border security measures, including the introduction of round-the-clock border surveillance using helicopters, drones and towers. Ottawa is also working with Washington on a North American 'joint strike force' to target organized crime groups that work across borders. Overall, Brosseau is taking a broad view of the fentanyl problem, stressing the need to hold those who profit from the drug accountable and make sure authorities have the needed tools, while also putting programs in place to help addicted people find a path to recovery. 'I call it an all-of-society approach,' he said. 'And the conversations I have with everybody (are) that there are no free rides in this.' Brosseau said the scourge of fentanyl and other opioids has become a concern on his street among 'parents like me' — part of a larger national conversation. He said he's in a position to provide some comfort and security to fellow parents worried about their children who might be exposed to drugs, and solace to those who are going through heartache by showing 'that we're going to do something about it.' This report by The Canadian Press was first published June 13, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Business Upturn
3 hours ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
